 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234 |
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jul 24, 2014
P4, N=10, Not yet recruiting, Sponsor: University of British Columbia
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: STRIB-PEP: Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. (clinicaltrials.gov) - Jul 23, 2014
P4, N=160, Not yet recruiting, Sponsor: Fundacion Clinic per a la Recerca Biomédica
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: Stribild HIV-2: An Open Label Trial of Stribild for Antiretroviral (ARV)-na (clinicaltrials.gov) - Jul 2, 2014
P4, N=30, Not yet recruiting, Sponsor: University of Washington
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Apr 27, 2014
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2013 --> Nov 2013
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Apr 27, 2014
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2013 --> Nov 2013 Trial completion date: Dec 2014 --> Nov 2014
- ||||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Apr 20, 2014
P3, N=1500, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Dec 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Apr 15, 2014
P3, N=708, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial completion date: Jun 2014 --> Dec 2014
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Apr 15, 2014
P3, N=700, Active, not recruiting, Sponsor: Gilead Sciences
Trial completion date: Jun 2014 --> Dec 2014 Trial completion date: Apr 2014 --> Jul 2014
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Feb 23, 2014
P2, N=71, Completed, Sponsor: Gilead Sciences
Trial completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- ||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: WAVES: Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (clinicaltrials.gov) - Feb 13, 2014
P3b, N=510, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Dec 23, 2013
P3, N=840, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Nov 18, 2013
P3b, N=48, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Oct 22, 2013
P3, N=840, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- efavirenz / Generic mfg.
Metastases: Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen (clinicaltrials.gov) - Aug 22, 2013
P=N/A, N=10, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial initiation date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jul 10, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Initiation date: Apr 2013 --> Jul 2013
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jul 10, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Apr 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: QUAD: HIV Non-Occupational Post-Exposure Prophylaxis (clinicaltrials.gov) - Jun 6, 2013
P4, N=120, Recruiting, Sponsor: Kenneth H. Mayer, MD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: QUAD: HIV Non-Occupational Post-Exposure Prophylaxis (clinicaltrials.gov) - May 15, 2013
P4, N=120, Recruiting, Sponsor: Kenneth H. Mayer, MD
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Mar 19, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- || Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Mar 19, 2013
P3, N=1500, Recruiting, Sponsor: Gilead Sciences
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Feb 20, 2013
P3, N=840, Active, not recruiting, Sponsor: Gilead Sciences
- |||||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Jan 29, 2013
P3, N=840, Active, not recruiting, Sponsor: Gilead Sciences
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Clinical: Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients (clinicaltrials.gov) - Jan 9, 2013
P=N/A, N=15, Recruiting, Sponsor: Massachusetts General Hospital
- ||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Jan 6, 2013
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Jan 6, 2013
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P2/3 trial: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Nov 1, 2012
P2/3, N=50, Recruiting, Sponsor: Gilead Sciences
- ||||| Tybost (cobicistat) / Gilead
Enrollment closed: Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment (clinicaltrials.gov) - Oct 9, 2012
P3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: PHI04: Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet (clinicaltrials.gov) - Sep 25, 2012
P3, N=30, Recruiting, Sponsor: Mehri McKellar, MD
- ||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Apr 24, 2012
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P2 trial: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Dec 21, 2011
P2, N=150, Active, not recruiting, Sponsor: Gilead Sciences
- |||||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Dec 18, 2011
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences
- |||||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Nov 17, 2011
P3, N=420, Active, not recruiting, Sponsor: Gilead Sciences